Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918 Requisition # HHSNIHOPCSBSS21-010760 Notice of Intent to Sole Source The National Institute of Health Office of Purchasing and Contracts intends to negotiate and award a contract to Biolegend Inc., to procure reagents to perform translational research evaluating the pathogenesis and treatment of high-consequence respiratory viral pathogens and inflammation. Respiratory infections are the leading cause of death in children worldwide and result in significant morbidity and mortality . This proposed procurement is for critical delivery services for which the government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b). The North American Industry Classification System (NAICS) code for this acquisition is 325414 and the size standard number of employees is 1200 This notice of intent to award is not a request for competitive quotations. Interested concerns capable of providing the same or similar services as described in this notice may submit a capability statement outlining their capabilities. No solicitation is available. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. The following verbiage is directly from the Justification for Other Than Full and Open Competition (JOFOC). Sole source determination is based on the need for safe, reliable, and delivery of products notification from the government. All responses are due to the Contract Specialist is June 14,2021 at 2:00 EST Government Official Designated for Receipt of Information Priscilla Abalos Contract Specialist Email:
[email protected] Phone: 301-594-5918